Bayoude Alamusi, Chang Hetong, Zhang Jiaxin, Wang Xiaoyan, Xie Yujun, Tilyek Akhtolkhyn, Chai Chengzhi
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China; Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Department of Pharmaceutical Chemistry and Pharmacognosy, Mongolian University of Pharmaceutical Sciences, Ulaanbaatar, 18130, Mongolia.
J Ethnopharmacol. 2025 Jul 24;351:120000. doi: 10.1016/j.jep.2025.120000. Epub 2025 Jun 7.
Ischemia-reperfusion (IR) injury is a major cause of acute kidney injury (AKI), characterized by disrupted renal metabolism and inflammation. Ribes diacanthum Pall. (RDP), a traditional Mongolian medicinal plant, shows promise in treating renal disorders, yet identifying its renoprotective compounds and mechanisms remains a challenge.
To develop a multi-dimensional analytical (M-DA) strategy for identifying the renoprotective components of RDP and elucidating their mechanisms in AKI treatment.
Initially, an IR-induced AKI mouse model was used to assess RDP in vivo effects. Subsequently, the chemical profile of RDP was analyzed using HPLC-QTOF-MS/MS, followed by network pharmacology and bioinformatics analysis to predict modulated signaling pathways. The involvement of core pathways was validated through western blotting, immunohistochemistry, and immunofluorescence analyses. Next, targeted cell extraction technology was employed to identify active compounds. Finally, in vitro activity assays were conducted to evaluate active compounds, and their interactions with key molecular targets were further analyzed using molecular docking and molecular dynamics simulations.
RDP treatment significantly reduced renal damage and dysfunction. Forty-one compounds were identified, with network pharmacology highlighting apoptosis and inflammation-related pathways. Validation confirmed that RDP modulates the PI3K/AKT and TLR2/NF-κB pathways. Three compounds-gallic acid, myricitrin, and eriodictyol-exhibited renoprotective effects in vitro and strong binding to AKT1 in computational simulations.
The M-DA strategy successfully identified three renoprotective compounds in RDP and their mechanisms of action. This novel approach not only advances the understanding of RDP therapeutic potential in AKI but also provides a valuable framework for the systematic exploration of bioactive compounds and their mechanisms in botanical medicine.
缺血再灌注(IR)损伤是急性肾损伤(AKI)的主要原因,其特征为肾脏代谢紊乱和炎症。蒙古传统药用植物刺果茶藨子(RDP)在治疗肾脏疾病方面显示出前景,但确定其肾脏保护化合物及其作用机制仍然是一项挑战。
制定一种多维分析(M-DA)策略,以鉴定RDP的肾脏保护成分并阐明其在AKI治疗中的作用机制。
首先,使用IR诱导的AKI小鼠模型评估RDP的体内作用。随后,采用高效液相色谱-四极杆飞行时间串联质谱(HPLC-QTOF-MS/MS)分析RDP的化学图谱,接着进行网络药理学和生物信息学分析以预测其调节的信号通路。通过蛋白质免疫印迹、免疫组织化学和免疫荧光分析验证核心通路的参与情况。接下来,采用靶向细胞提取技术鉴定活性化合物。最后,进行体外活性测定以评估活性化合物,并使用分子对接和分子动力学模拟进一步分析它们与关键分子靶点的相互作用。
RDP治疗显著减轻了肾脏损伤和功能障碍。鉴定出41种化合物,网络药理学突出了凋亡和炎症相关通路。验证证实RDP调节PI3K/AKT和TLR2/NF-κB通路。三种化合物——没食子酸、杨梅苷和圣草酚——在体外表现出肾脏保护作用,并且在计算机模拟中与AKT1有强烈结合。
M-DA策略成功鉴定出RDP中的三种肾脏保护化合物及其作用机制。这种新方法不仅推进了对RDP在AKI中治疗潜力的理解,还为系统探索植物药中的生物活性化合物及其作用机制提供了有价值的框架。